Compugen Ltd

NASDAQ:CGENUnited States

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Contact Information

Headquarters

Azrieli Center, 26 Harokmim St., Bldg DHOLON, Israel 5885849

Phone

---

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Paul Sekhri

President, Chief Executive Officer, Director

Anat Cohen-Dayag

Chief Financial Officer

David Silberman

Senior Vice President, Corporate and Business Development

Oliver Froescheis

Senior Vice President, Technology Innovation

Zurit Levine